TY - JOUR
TI - Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure
AU - Seferović, P.M.
AU - Fragasso, G.
AU - Petrie, M.
AU - Mullens, W.
AU - Ferrari, R.
AU - Thum, T.
AU - Bauersachs, J.
AU - Anker, S.D.
AU - Ray, R.
AU - Çavuşoğlu, Y.
AU - Polovina, M.
AU - Metra, M.
AU - Ambrosio, G.
AU - Prasad, K.
AU - Seferović, J.
AU - Jhund, P.S.
AU - Dattilo, G.
AU - Čelutkiene, J.
AU - Piepoli, M.
AU - Moura, B.
AU - Chioncel, O.
AU - Ben Gal, T.
AU - Heymans, S.
AU - Jaarsma, T.
AU - Hill, L.
AU - Lopatin, Y.
AU - Lyon, A.R.
AU - Ponikowski, P.
AU - Lainščak, M.
AU - Jankowska, E.
AU - Mueller, C.
AU - Cosentino, F.
AU - Lund, L.H.
AU - Filippatos, G.S.
AU - Ruschitzka, F.
AU - Coats, A.J.S.
AU - Rosano, G.M.C.
JO - European Journal of Heart Failure
PY - 2020
VL - 22
TODO - 11
SP - 1984-1986
PB - John Wiley and Sons Ltd
SN - null
TODO - 10.1002/ejhf.2026
TODO - canagliflozin;  dapagliflozin;  empagliflozin;  ertugliflozin;  sodium glucose cotransporter 2 inhibitor;  SLC5A2 protein, human;  sodium glucose cotransporter 2, all cause mortality;  Article;  cardiovascular mortality;  cardiovascular risk;  chronic kidney failure;  diabetic patient;  estimated glomerular filtration rate;  Europe;  follow up;  heart failure;  high risk patient;  hospitalization;  human;  kidney function;  non insulin dependent diabetes mellitus;  outcome assessment;  priority journal;  risk reduction;  heart failure;  metabolism, Diabetes Mellitus, Type 2;  Heart Failure;  Humans;  Sodium-Glucose Transporter 2;  Sodium-Glucose Transporter 2 Inhibitors
TODO - The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus. © 2020 European Society of Cardiology
ER -